Stockreport

A rare setback as Ozempic-maker Novo Nordisk takes a $820 million hit as its next wonder drug fails [Fortune]

BAYER AG S/ADR  (BAYRY) 
NASDAQ:AMEX Investor Relations: investor.bayer.com
PDF The Danish drugmaker stopped the trial partway through, after an independent monitoring committee concluded that it hadn't hit its main goal of changing blood pressure [Read more]